[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4011
6. Mallouk A, Pham PT, Pham PC: Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol; 2006 Dec;10(4):284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In solid tumors, the NS is most often due to membranous glomerulonephropathy, whereas in common hematological malignancies, minimal-change disease predominates.
  • METHODS: We report a case of the simultaneous diagnoses of FSGS and Hodgkin's lymphoma, and review the literature on various nephrotic glomerulonephropathies associated with common leukemia and lymphoma.
  • RESULTS: Although nephrotic glomerulonephropathies rarely occur in association with acute leukemia, they have often been described in chronic lymphocytic leukemia (CLL).
  • While minimal-change disease is most commonly found in association with Hodgkin's lymphoma, more diverse and complex renal lesions are associated with non-Hodgkin's lymphoma.
  • [MeSH-major] Glomerulosclerosis, Focal Segmental / complications. Hodgkin Disease / complications
  • [MeSH-minor] Adult. Glomerulonephritis / etiology. Humans. Leukemia / complications. Lymphoma / complications. Male. Nephrotic Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nephrol. 1986 Dec;26(6):311-3 [3802598.001]
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi45-51 [12953042.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):362-74 [15129648.001]
  • [Cites] Am J Kidney Dis. 1998 Nov;32(5):785-93 [9820448.001]
  • [Cites] Scand J Work Environ Health. 1985;11 Suppl 1:83-90 [3906873.001]
  • [Cites] Lancet. 1974 Sep 7;2(7880):556-60 [4140273.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2083-92 [12533032.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • [Cites] Mayo Clin Proc. 1983 Sep;58(9):568-77 [6887974.001]
  • [Cites] Am J Kidney Dis. 1994 Jun;23(6):773-83 [8203357.001]
  • [Cites] Postgrad Med J. 1988 May;64(751):395-7 [3200784.001]
  • [Cites] Kidney Int. 1992 Jul;42(1):127-35 [1635342.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):605-9 [15468431.001]
  • [Cites] Br Med J. 1922 Dec 23;2(3234):1201-1208.2 [20770949.001]
  • [Cites] J Pathol. 2002 Aug;197(5):677-83 [12210089.001]
  • [Cites] J Clin Pathol. 1995 Feb;48(2):160-3 [7745117.001]
  • [Cites] South Med J. 1989 Sep;82(9):1187-9 [2772690.001]
  • [Cites] N Engl J Med. 1983 Apr 14;308(15):888-96 [6835286.001]
  • [Cites] Ann Intern Med. 1966 Jan;64(1):41-51 [5900782.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):107-14 [10561025.001]
  • [Cites] Rev Clin Exp Hematol. 2000 Mar;4(1):5-21 [11491097.001]
  • [Cites] Nephrology (Carlton). 2004 Dec;9(6):387-91 [15663641.001]
  • [Cites] Am J Kidney Dis. 2003 Oct;42(4):631-57 [14520615.001]
  • [Cites] Am J Kidney Dis. 2005 Aug;46(2):278-82 [16112046.001]
  • [Cites] Am J Nephrol. 1983 Jul-Aug;3(4):228-32 [6688503.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Am J Kidney Dis. 1994 May;23(5):743-6 [8172220.001]
  • [Cites] Ann Intern Med. 1994 Nov 15;121(10):818 [7944068.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):874-5 [4016678.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5982-90 [10557087.001]
  • (PMID = 17186334.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


7. Duff K: You can make a difference in the administration of intravenous immunoglobulin therapy. J Infus Nurs; 2006 May-Jun;29(3 Suppl):S5-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravenous immunoglobulin is a preparation of immune globulins containing antibodies given intravenously to patients with both inherited and acquired immunodeficiency disorders, such as primary immune deficiency diseases, idiopathic thrombocytopenia purpura, chronic lymphocytic leukemia, and bone marrow transplantation.
  • [MeSH-minor] Bone Marrow Transplantation. Drug Monitoring / nursing. Humans. Immunologic Deficiency Syndromes / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Nursing Assessment. Patient Education as Topic. Patient Selection. Purpura, Thrombocytopenic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878850.001).
  • [ISSN] 1533-1458
  • [Journal-full-title] Journal of infusion nursing : the official publication of the Infusion Nurses Society
  • [ISO-abbreviation] J Infus Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors
  • [Number-of-references] 35
  •  go-up   go-down


8. Smit LA, van Maldegem F, Langerak AW, van der Schoot CE, de Wit MJ, Bea S, Campo E, Bende RJ, van Noesel CJ: Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. Haematologica; 2006 Jul;91(7):903-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation.
  • It has been proposed that aberrant targeting of the somatic hypermutation machinery is instrumental in initiation and progression of B-cell non Hodgkin's lymphomas.
  • In this study, we investigated the B-cell receptor and the role of the somatic hypermutation machinery in B-cell chronic lymphocytic leukemias (B-CLL) prior to and after transformation to a lymphoma of a higher malignancy grade (Richter's transformation).
  • DESIGN AND METHODS: We investigated the activity of the somatic hypermutation machinery in nine B-CLL and secondary diffuse large B-cell lymphomas by measuring the expression of activation-induced cytidine deaminase, in combination with mutation analysis of immunoglobulin (Ig) and non-Ig genes.
  • Furthermore, activated-induced cytidine deaminase expression and somatic hypermutation activity of most RS B-CLL were found to be higher than those of control (non-transforming) B-CLL.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Receptors, Antigen / immunology. Somatic Hypermutation, Immunoglobulin

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2006 Jul;91(7):867 [16818267.001]
  • (PMID = 16818277.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Receptors, Antigen
  •  go-up   go-down


9. Kahwash R, Rugg SS, Smith MD: Relapsing B-cell lymphoblastic leukemia in an adult presenting as an infiltrative cardiac mass with tamponade. J Am Soc Echocardiogr; 2007 Nov;20(11):1319.e1-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsing B-cell lymphoblastic leukemia in an adult presenting as an infiltrative cardiac mass with tamponade.
  • We present a case of a 51-year-old man with a history of bone-marrow transplantation for acute lymphoblastic leukemia who returned 4 months later with cardiac tamponade.
  • An echocardiogram showed a solid mass encasing the right ventricle (RV).
  • Surgical biopsy of the mass revealed early relapse with lymphoblasts derived from B-cell precursors.
  • We believe that this is the first description of relapsing B-cell acute lymphoblastic leukemia presenting as an intrathoracic mass with direct invasion of the adjacent cardiac structures causing tamponade physiology.
  • [MeSH-major] Cardiac Tamponade / etiology. Cardiac Tamponade / ultrasonography. Heart Neoplasms / etiology. Heart Neoplasms / ultrasonography. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / ultrasonography

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658241.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, Greco G, Ciuffreda L, Mestice A, Liso A: Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med; 2005 Apr;145(4):212-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
  • In this study we prospectively evaluated serial measurements of serum cardiac markers and echocardiography in patients with de novo acute myeloid and lymphoid leukemias (AML and ALL, respectively) treated with anthracyclines.
  • [MeSH-major] Anthracyclines / adverse effects. Antibiotics, Antineoplastic / adverse effects. Heart Diseases / blood. Heart Diseases / chemically induced. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Troponin I / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962840.001).
  • [ISSN] 0022-2143
  • [Journal-full-title] The Journal of laboratory and clinical medicine
  • [ISO-abbreviation] J. Lab. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Troponin I
  •  go-up   go-down


11. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood; 2007 Jan 15;109(2):740-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
  • Arsenic trioxide (As2O3) is highly efficacious in acute promyelocytic leukemia (APL).
  • In 10 of 11 myeloid and lymphoid leukemia lines, quantitative polymerase chain reaction (Q-PCR) and Western blotting showed that AQP9 expression correlated positively with As2O3-induced cytotoxicity.
  • Similarly, the chronic myeloid leukemia line K562 expressed low levels of AQP9 and was As2O3 insensitive.
  • Pretreatment of the myeloid leukemia line HL-60 with all-trans retinoic acid (ATRA) up-regulated AQP9, leading to a significantly increased arsenic uptake and As2O3-induced cytotoxicity on incubation with As2O3, which might explain the synergism between ATRA and As2O3.
  • Q-PCR showed that primary APL cells expressed AQP9 significantly (2-3 logs) higher than other acute myeloid leukemias (AMLs), which might explain their exquisite As2O3 sensitivity.
  • [MeSH-major] Aquaporins / metabolism. Arsenicals / pharmacology. Leukemia, Myeloid / metabolism. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Oxides / pharmacology
  • [MeSH-minor] Acute Disease. Cell Line, Tumor. Cell Proliferation / drug effects. Gene Expression Profiling. Humans. K562 Cells. Point Mutation. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity. Tretinoin / pharmacology. Up-Regulation / drug effects

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968895.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP9 protein, human; 0 / Aquaporins; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


12. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC: Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol; 2010 Nov 20;28(33):4919-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
  • We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia.
  • PATIENTS AND METHODS: Thirty-one adults with acute myeloid leukemia (AML) and four adults with acute lymphoblastic leukemia (ALL) were enrolled.
  • Two of four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after development of cutaneous graft-versus-host disease, without donor leukocyte infusion.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thalidomide / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7 [16399569.001]
  • [Cites] Br J Cancer. 2005 Sep 19;93(6):613-9 [16222306.001]
  • [Cites] Blood. 2006 Jul 15;108(2):618-21 [16569772.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11 [17576924.001]
  • [Cites] J Clin Pharmacol. 2007 Dec;47(12):1466-75 [17954615.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):36-45 [17995965.001]
  • [Cites] Blood. 2008 Jan 1;111(1):86-93 [17893227.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Cancer Immunol Immunother. 2008 Dec;57(12):1849-59 [18392823.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1002-5 [18824593.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5 [19332800.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3947-52 [18987358.001]
  • [Cites] J Clin Pharmacol. 2009 Jun;49(6):650-60 [19451403.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9 [19470455.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4027-33 [19710500.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):217-25 [19804455.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):596-604 [20026798.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):556-61 [20026803.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):549-55 [20026805.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1204-13 [19965644.001]
  • [Cites] Blood. 2010 Mar 11;115(10):2077-87 [20053754.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2619-29 [19965642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8 [20368434.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2389-95 [20385984.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1157-63 [11149725.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 1997 Jun 1;89(11):4226-35 [9166868.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S9-12 [9272127.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):965-70 [15806131.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30 [16085014.001]
  • [Cites] Future Oncol. 2005 Oct;1(5):575-83 [16556034.001]
  • (PMID = 20956622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / K23 CA120708; United States / NCI NIH HHS / CA / P50-CA140158; United States / NCI NIH HHS / CA / K23CA120708; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC3020696
  •  go-up   go-down


13. San Juan AF, Fleck SJ, Chamorro-Viña C, Maté-Muñoz JL, Moral S, Pérez M, Cardona C, Del Valle MF, Hernández M, Ramírez M, Madero L, Lucia A: Effects of an intrahospital exercise program intervention for children with leukemia. Med Sci Sports Exerc; 2007 Jan;39(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of an intrahospital exercise program intervention for children with leukemia.
  • PURPOSE: The purpose was to investigate the effect of a 16-wk intrahospital supervised conditioning program including both resistance and aerobic training and a 20-wk detraining period on measures of aerobic fitness, muscular strength, functional mobility, ankle range of motion, and quality of life (QOL) in children receiving treatment for acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Exercise / physiology. Hospitals, Pediatric. Leukemia. Weight Lifting / physiology

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218878.001).
  • [ISSN] 0195-9131
  • [Journal-full-title] Medicine and science in sports and exercise
  • [ISO-abbreviation] Med Sci Sports Exerc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Erduran E, Tekelioglu Y, Karakas T, Gedik Y, Mert FM: Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2006 Oct-Nov;23(7):587-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia.
  • The authors compare the apoptotic effect on the lymphoblasts and the proliferative effect on the myeloid lineage cells of a short-course high-dose methylprednisolone (HDMP) and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia (ALL).
  • The apoptotic percentages of lymphpblasts and the percentages of blasts and myeloid lineage cells were determined after performing the bone marrow aspiration (BMA) at diagnosis on the 0th, 3rd, and 7th days of the treatments in all patients.
  • [MeSH-major] Apoptosis / drug effects. Lymphocytes / drug effects. Methylprednisolone / administration & dosage. Myeloid Cells / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / administration & dosage
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Antigens, CD13 / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Cell Lineage. Child. Child, Preschool. Female. Humans. Infant. Male. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928654.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 9PHQ9Y1OLM / Prednisolone; EC 3.4.11.2 / Antigens, CD13; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


15. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricò M: Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol; 2005 Oct 1;23(28):7161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
  • PURPOSE: Between September 1991 and May 1997, within the International Berlin-Frankfurt-Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing the efficacy of prolonged use of high-dose l-asparaginase (HD-l-ASP) during continuation therapy in children with standard risk (SR) acute lymphoblastic leukemia (ALL), treated with a reduced BFM-type chemotherapy.
  • Treatment consisted of a BFM-type modified backbone with omission of the IB part in induction and elimination of two doses of anthracyclines during reinduction in both arms at the beginning of continuation therapy.
  • After a median follow-up of 9 years, the probability of disease-free survival at 10 years was 87.5% (SE, 2.5) for YES-ASP arm versus 78.7% (SE, 3.3) for NO-ASP arm (P = .03).
  • CONCLUSION: In this subset of patients, selected with criteria not including monitoring of minimal residual disease, application of extended HD-l-ASP may improve prognosis, compensating reduced leukemia control that results from adoption of a reduced-intensity BFM-backbone for treatment of children with SR ALL.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192600.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


16. Matsuzaki A, Nagatoshi Y, Inada H, Nakayama H, Yanai F, Ayukawa H, Kawakami K, Moritake H, Suminoe A, Okamura J: Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group. Pediatr Blood Cancer; 2005 Aug;45(2):111-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
  • BACKGROUND: The treatment results of childhood acute lymphoblastic leukemia (ALL) with a first relapse were retrospectively analyzed to determine prognostic factors.
  • In particular, an attempt was made to clarify whether stem cell transplantation (SCT) had any advantages over chemotherapy.
  • The potential prognostic factors examined were: the time of initial diagnosis, gender, immunophenotype of leukemic blasts and the NCI-risk classification at initial diagnosis, the site of relapse, the time of relapse (early: within 18 months after diagnosis, intermediate: other than either early or late relapse, late: later than 6 months after the discontinuation of front-line chemotherapy), and the treatment after relapse (chemotherapy alone and SCT).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Japan / epidemiology. Male. Multivariate Analysis. Prognosis. Proportional Hazards Models. Recurrence. Retrospective Studies. Risk


17. Baillargeon J, Langevin AM, Lewis M, Grady JJ, Thomas PJ, Mullins J, Estrada J, Pitney A, Sacks N, Pollock BH: Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia. Cancer; 2005 Apr 15;103(8):1725-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia.
  • BACKGROUND: The objective of this study was to examine changes over time in body mass index (BMI) from diagnosis through chemotherapy for pediatric patients with B-precursor acute lymphoblastic leukemia (ALL).
  • METHODS: The study cohort consisted of 141 white Hispanic pediatric patients who were diagnosed with ALL and were treated at 2 South Texas pediatric oncology centers between 1993 and 2002.
  • CONCLUSIONS: Although it is known that leukemia therapy is associated with prevalent obesity in survivorship, its pattern of development during therapy has not been elucidated.
  • In the current cohort of Hispanic children with ALL, BMI scores were elevated at diagnosis (mean +/- standard deviation standardized BMI Z score, 0.33 +/- 1.4), then increased, and remained elevated for the entire duration of chemotherapy.
  • Patients who were classified as normal weight exhibited an increase in BMI over time; patients who were classified as overweight at diagnosis exhibited BMI patterns that were relatively stable; and patients who were classified as obese exhibited a very slight decline over time.
  • [MeSH-major] Body Mass Index. Obesity / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15754333.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11078
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T, Takahashi Y, Kuno T, Sugita K, Sato T, Kato K, Ogawa A, Nakahata T, Mizutani S, Horibe K, Ishii E, Japan Infant Leukemia Study Group: Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood; 2006 Jun 15;107(12):4663-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group.
  • Although infants with acute lymphoblastic leukemia (ALL) and a germline MLL gene have a better prognosis than comparable infants with a rearranged MLL gene, their optimal therapy is controversial.
  • All 21 infants with precursor B-cell ALL have been in first complete remission for 3.5 to 8.8 years.
  • These results indicate that chemotherapy of the type described here is both safe and highly effective against infant precursor B-cell ALL with MLL in the germline configuration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Myeloid-Lymphoid Leukemia Protein
  • [MeSH-minor] Disease-Free Survival. Female. Histone-Lysine N-Methyltransferase. Humans. Infant. Japan. Male. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478880.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


19. Zenz T, Döhner K, Denzel T, Döhner H, Stilgenbauer S, Bullinger L: Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol; 2008 May;141(5):742-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Proto-Oncogene Proteins c-akt / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410456.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / platelet protein P47; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


20. Liang DC, Yang CP, Lin DT, Hung IJ, Lin KH, Chen JS, Hsiao CC, Chang TT, Peng CT, Lin MT, Chang TK, Jaing TH, Liu HC, Wang LY, Yeh TC, Jou ST, Lu MY, Cheng CN, Sheen JM, Chiou SS, Wu KH, Hung GY, Chen RL, Chen SH, Cheng SN, Chang YH, Chen BW, Ho WL, Wang JL, Lin ST, Hsieh YL, Wang SC, Chang HH, Yang YL, Huang FL, Chang CY, Chang WH, Lin KS: Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia; 2010 Feb;24(2):397-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.
  • The long-term outcome of 1390 children with acute lymphoblastic leukemia (ALL), treated in two successive clinical trials (Taiwan Pediatric Oncology Group (TPOG)-ALL-97 and TPOG-ALL-2002) between 1997 and 2007, is reported.
  • High-risk B-lineage ALL, T-cell, CD10 negativity, t(9;22), infant, and higher leukocyte count were consistently adverse factors, whereas hyperdiploidy >50 was a consistently favorable factor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


21. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD: Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol; 2009 Dec;37(12):1435-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Dasatinib (SPRYCEL, BMS-354825) is a small molecule Src/Abl tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • The production of TNF-alpha was also impaired in vitro in response to TLR3, TLR4, and TLR9 stimulation of the mouse macrophage cell line RAW264.7, as well as TLR4 and TLR9 stimulation of BMDM; IL-6 production was also impaired in dasatinib-treated BMDM.
  • [MeSH-minor] Animals. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Cell Line. Cells, Cultured. Dasatinib. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Injections, Intraperitoneal. Interleukin-10 / blood. Interleukin-10 / metabolism. Interleukin-6 / blood. Interleukin-6 / metabolism. Lipopolysaccharides / administration & dosage. Lung / drug effects. Lung / metabolism. Mice. Mice, Inbred C57BL. Mice, Inbred Strains. Neutrophils / cytology. Neutrophils / drug effects. Toll-Like Receptor 3 / metabolism. Toll-Like Receptor 4 / metabolism. Toll-Like Receptor 9 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786067.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Pyrimidines; 0 / TLR3 protein, mouse; 0 / Thiazoles; 0 / Tlr4 protein, mouse; 0 / Tlr9 protein, mouse; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; RBZ1571X5H / Dasatinib
  •  go-up   go-down


22. Cen D, Lü JX, Pei RZ, Tu ZG, Yu XL, Wen YA: [The clinical significance of real-time fluorescence PCR quantification of hepatocyte growth factor mRNA expression in acute leukemia]. Zhonghua Nei Ke Za Zhi; 2008 May;47(5):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical significance of real-time fluorescence PCR quantification of hepatocyte growth factor mRNA expression in acute leukemia].
  • OBJECTIVE: To detect quantitatively hepatocyte growth factor (HGF) mRNA expressions of bone marrow mononuclear cells (MNCs) in acute leukemia (AL) and investigate its clinical significance.
  • METHODS: Total mRNA of quantitated bone marrow MNCs isolated from 67 de novo AL cases was extracted and then cDNA was synthesized.
  • RESULTS: Expressions of HGF mRNA in a group of AL were higher significantly than these in a control group (6.936 +/- 1.613, 0.407 +/- 0.170, P < 0.001), but there was similarity between a group of acute myeloid leukemia (AML) and group of acute lymphoblastic leukemia (ALL) (7.127 +/- 1.911, 6.635 +/- 0.934, P > 0.05).
  • In addition, expressions of HGF mRNA in the remission group were lower than these in the non-remission group (6.393 +/- 1.165, 8.041 +/- 1.848, P < 0.005).
  • It is suggested that HGF mRNA is a suitable index for AL diagnosis and treatment.
  • [MeSH-major] Hepatocyte Growth Factor / genetics. Leukemia / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Child, Preschool. Female. Fluorescence. Gene Expression Regulation, Leukemic. Humans. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953951.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


23. Zhang W, Fu R, Liu WH, Cheng YQ, Song WX, DU LJ, Ruan EB, Zhang LT, Wang XM, Liang Y, Wang GJ, Qu W, Song J, Zhang RL, Guan J, Li LJ, Zou P, Shao ZH: [Prognosis and related factors of acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct;15(5):1102-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and related factors of acute lymphoblastic leukemia].
  • In order to analyze the prognosis and related factors of acute lymphoblastic leukemia (ALL), 53 newly diagnosed ALL patients were enrolled in this study.
  • White blood cell count and hemoglobin level of newly diagnosed patients were significantly correlated with OS and EFS.
  • In order to decrease the relapse rate and prolong the EFS, individual therapeutical regimens and prophylaxis of complicating diseases should be applied to ALL patients.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956700.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T, Koliouskas D, Athanassiadou F: Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol; 2007 Aug;86(2):166-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
  • We prospectively studied 49 children (26 boys and 23 girls) with acute lymphoblastic leukemia (ALL) (median age, 5.5 years; range, 15 months to 12.5 years) who were treated with the BFM95 chemotherapy protocol.
  • Expression of each of the MDR genes was independent of the initial white blood cell count, immunophenotype, National Cancer Institute risk classification, and prednisone response.
  • Interestingly, MDR1 expression was significantly higher at relapse than at diagnosis for 4 sample pairs.
  • Evaluation of MDR1 expression at diagnosis of childhood ALL may contribute to the early identification of patients at risk of treatment failure.
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Drug Resistance, Multiple / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Vault Ribonucleoprotein Particles / genetics


25. Khalilzadeh A, Wangoo KT, Morris DL, Pourgholami MH: Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol; 2007 Aug 1;74(3):407-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we assess the role of apoptotic mediators in eliciting an anti-proliferative response to paclitaxel (PTX) in a T cell acute lymphoblastic leukemia (ALL) cell line CEM and its epothilone-paclitaxel resistant sub-line CEM/dEpoB300.
  • In cell proliferation studies, CEM cells were sensitive to both PTX and ABZ, while the CEM/dEpoB300 cells were highly resistant to PTX (IC(50) 2.86 nM versus 30.26 nM, respectively).
  • These results reveal for the first time, the changes in apoptotic mediators following development of resistance to PTX in an ALL cell and the significantly increased sensitivity of these PTX resistant cells to ABZ.
  • [MeSH-major] Albendazole / pharmacology. Apoptosis / drug effects. Epothilones / pharmacology. Paclitaxel / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Base Sequence. Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation. Cytochromes c / metabolism. DNA Primers. Humans. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560963.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Epothilones; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3; F4216019LN / Albendazole; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Ma X, Buffler PA, Wiemels JL, Selvin S, Metayer C, Loh M, Does MB, Wiencke JK: Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev; 2005 Aug;14(8):1928-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic difference in daycare attendance, early infections, and risk of childhood acute lymphoblastic leukemia.
  • A role for infectious agents has been proposed in the etiology of childhood acute lymphoblastic leukemia (ALL), particularly for common ALL (c-ALL; ALL diagnosed in children ages 2-5 years and expressing CD10 and CD19 surface antigens).
  • We evaluated the possible etiologic role of daycare attendance (a proxy measure for exposure to infectious agents) and infections during infancy in the Northern California Childhood Leukemia Study.
  • In non-Hispanic White children, daycare attendance measured by child-hours was associated with a significantly reduced risk of ALL.
  • The magnitude of effect associated with the same number of child-hours was stronger for daycare attendance during infancy than for daycare attendance before diagnosis.
  • In addition, self-reported ear infection during infancy was associated with a significantly reduced risk of c-ALL (OR, 0.32; 95% CI, 0.14-0.74) in non-Hispanic White children.
  • These results offer indirect yet strong support for the infectious disease hypothesis in the etiology of ALL in non-Hispanic White children and highlight an important ethnic difference.
  • [MeSH-major] Child Day Care Centers. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Child Care.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103439.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


27. Luo CY, Li BS, Jiang H, Gu LJ: [Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):446-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia].
  • OBJECTIVE: To determine whether the high level of asparagine synthetase (AS) expression in childhood acute lymphocytic leukemia (ALL) is associated with an inferior prognosis.
  • The two-year estimated disease free survival was much lower in children with high AS expression (53.8%) than in those with low AS expression (84.6%) (P<0.05).
  • [MeSH-major] Aspartate-Ammonia Ligase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035175.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


28. Zwick D, Cooley L, Hetherington M: Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods. Lab Hematol; 2006;12(2):75-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
  • The detection and quantification of minimal residual leukemia (MRD) has importance for monitoring continued disease response and detection of early relapse.
  • We retrospectively compared MRD detection rates and percentages of residual leukemia by flow cytometry immunophenotyping (FCIP) with results obtained by either flow cytometry DNA (FCDNA) ploidy (n = 14) and/or fluorescent in situ hybridization (FISH) (n = 33) testing for cases with 1.5% or less residual leukemia.
  • A total of 42 paired results were obtained from 20 pediatric patients, including 16 with B lineage acute lymphocytic leukemia and 4 patients with acute myeloid leukemia during the course of induction and/or relapse.
  • There was reasonable correlation coefficients for quantity of residual disease by FCIP and FCDNA ploidy, and poor correlation coefficients for levels of residual disease between FCIP- and FISH-based results.
  • [MeSH-major] Flow Cytometry / methods. Leukemia / diagnosis. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Acute Disease. Diagnostic Techniques and Procedures / standards. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Ploidies. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751134.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Ulusoy G, Adali O, Tumer TB, Sahin G, Gozdasoglu S, Arinç E: Significance of genetic polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia. Oncology; 2007;72(1-2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of genetic polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia.
  • BACKGROUND/AIMS: The molecular etiology of childhood acute lymphoblastic leukemia (ALL) is likely to involve interactions between environmental factors and genetic make up.
  • Understanding these interactions between various predisposing genes for the risk of developing childhood leukemia is of considerable importance.
  • The CYP2E1 gene possesses several polymorphisms in humans, and among them, CYP2E1*5B and *6 have been shown to be associated with increased risks of several chemical-induced diseases.
  • [MeSH-major] Cytochrome P-450 CYP2E1 / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 18025800.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 1.14.13.- / Cytochrome P-450 CYP2E1
  •  go-up   go-down


30. Sun J, Huang H, Zhu YY, Lan JP, Li JY, Lai XY, Yu J: Study on the expression and mutation of human telomeric repeat binding factor (hTRF1) in 10 malignant hematopoietic cell lines. J Zhejiang Univ Sci B; 2005 Dec;6(12):1141-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study on the expression and mutation of human telomeric repeat binding factor (hTRF1) in 10 malignant hematopoietic cell lines.
  • OBJECTIVE: Detecting the expression and mutation of human telomeric repeat binding factor (hTRF1) in 10 malignant hematopoietic cell line cells on the base of determining its genomic structure and its four pseudogenes to clarify if hTRF1 mutation is one of the factors of the activation of telomerase.
  • Real-time RT-PCR was used to detect the expression of hTRF1mRNA in 10 cell line cells, including myelogenous leukemia cell lines K562, HL-60, U-937, NB4, THP-1, HEL and Dami; lymphoblastic leukemia cell lines 6T-CEM, Jurkat and Raji.
  • PCR and sequencing were used to detect mutation of each exon of hTRF1 in 10 cell line cells.
  • All cell line cells showed positive telomerase activity.
  • The expression of hTRF1 was significantly lower in malignant hematopoietic cell lines cells (0.0338, 0.0108-0.0749) than in normal mononuclear cells (0.0493, 0.0369-0.128) (P=0.004).
  • But no significant mutation was found in all exons of hTRF1 in 10 cell line cells.
  • CONCLUSION: hTRF1 mutation is probably not one of the main factors for telomerase activation in malignant hematopoietic disease.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor / metabolism. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease / genetics. Humans. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Feb 1;28(3):669-77 [10637317.001]
  • [Cites] Oncol Rep. 2000 Sep-Oct;7(5):987-90 [10948327.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):593-8 [11179492.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1497-508 [11313893.001]
  • [Cites] Cell. 2001 Nov 2;107(3):347-59 [11701125.001]
  • [Cites] Science. 1998 Nov 20;282(5393):1484-7 [9822378.001]
  • [Cites] Exp Neurol. 2004 Aug;188(2):238-45 [15246823.001]
  • [Cites] Annu Rev Genet. 1985;19:253-72 [3909943.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1663-7 [7502076.001]
  • [Cites] Nature. 1997 Feb 20;385(6618):740-3 [9034193.001]
  • [Cites] Somat Cell Mol Genet. 1997 Jul;23(4):275-86 [9542529.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1315-20 [12168944.001]
  • (PMID = 16358369.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / TERF1 protein, human; 0 / Telomere-Binding Proteins
  • [Other-IDs] NLM/ PMC1390634
  •  go-up   go-down


31. Haarman EG, Kaspers GJ, Pieters R, Rottier MM, Veerman AJ: Circumvention of glucocorticoid resistance in childhood leukemia. Leuk Res; 2008 Sep;32(9):1417-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circumvention of glucocorticoid resistance in childhood leukemia.
  • In this study, we determined if in vitro resistance to prednisolone and dexamethasone could be circumvented by cortivazol or methylprednisolone, or reversed by meta-iodobenzylguanidine in pediatric lymphoblastic and myeloid leukemia.
  • As there were strong correlations between the LC50 values (drug concentration inducing 50% leukemic cell kill, LCK) of the different glucocorticoids and median prednisolone/methylprednisolone, prednisolone/dexamethasone and prednisolone/cortivazol LC50 ratios did not differ between the leukemia subtypes, we conclude that none of the glucocorticoids had preferential anti-leukemic activity.
  • Meta-iodobenzylguanidine however, partially reversed glucocorticoid resistance in 19% of the lymphoblastic leukemia samples.
  • [MeSH-major] Drug Resistance, Neoplasm. Glucocorticoids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Methylprednisolone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pregnatrienes / therapeutic use
  • [MeSH-minor] Cell Proliferation. Child. Dexamethasone / therapeutic use. Drug Screening Assays, Antitumor. Humans. Prednisolone / therapeutic use. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glucocorticoid Resistance.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395253.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Pregnatrienes; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone; YM183K0H63 / cortivazol
  •  go-up   go-down


32. Abramenko I, Bilous N, Kryachok I, Filonenko I, Pilipenko G, Chumak A, Bazyka D, Bebeshko V: IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine. Exp Oncol; 2007 Sep;29(3):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
  • THE AIM of the study was to evaluate the frequency of IGHV3-21 gene usage and its clinical significance for patients with B-cell chronic lymphocytic leukemia (CLL) in Ukraine.
  • [MeSH-major] Gene Expression. Genes, Immunoglobulin Heavy Chain. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasms, Second Primary / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18004251.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region
  •  go-up   go-down


33. Rihani R, Bazzeh F, Faqih N, Sultan I: Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer; 2010 Sep 15;116(18):4385-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary cancer and histological subtype, incidence, risk factors, outcomes, and changes in risk patterns of secondary hematological malignancies were analyzed for 1973 to 1985, 1986 to 1995, and 1996 to 2005.
  • The main histological subtype of secondary hematological malignancy was acute myeloid leukemia (AML) (49%), which had the shortest median latency time and the worst 5-year survival (18% ± 5.3%; P = .044).
  • The risk of secondary AML steadily increased from 1986 to 2005, whereas SIRs for acute lymphoblastic leukemia did not change over time.
  • Non-Hodgkin lymphoma, the second most common secondary hematological malignancy, occurred at a median of 112 months, and its risk steadily increased over time periods.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20549819.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. El-Gohary GM, Azzam HM, Ahmed OI, El-Shokry MH: Pro-inflammatory cytokines and depression in patients with acute leukemia. Egypt J Immunol; 2008;15(1):13-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pro-inflammatory cytokines and depression in patients with acute leukemia.
  • The aim of present study was to investigate the relation between pro-infammatory cytokines [Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha)], depression and stressful life events in patients with acute leukemia.
  • Twenty eight patients (18 males and 10 females) suffering from acute leukemia participated in this study.
  • Although, TNF-a gene expression was not associated with depression or stressful life events, it was associated with acute myeloblastic leukemia (AML).
  • IL-6 gene expression was much higher among patients with AML than acute lymphoblastic leukemia (ALL), but the difference did not reach statistical significance.


35. Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U: Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer; 2009 Jan;52(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: MTX, 5-methyltetrahydrofolate, calcium folinate, S-adenosylmethionine, and S-adenosylhomocysteine were measured in the cerebrospinal fluid (CSF) of 29 patients with acute lymphoblastic leukemia (ALL) who were treated with high-dose MTX (5 g/m(2)) followed by calcium folinate rescue (3 x 15 mg/m(2)) and/or intrathecal (8-12 mg) MTX.
  • RESULTS: In non-toxic patients, CSF concentrations of 5-methyltetrahydrofolate and S-adenosylmethionine were in the normal range 2 weeks after administration of high-dose and intrathecal MTX followed by rescue.
  • S-adenosylhomocysteine was determined in all samples of neurotoxic patients but was below the limit of quantification in most samples of non-toxic patients.
  • [MeSH-major] Cerebrospinal Fluid / metabolism. Folic Acid / metabolism. Metabolic Networks and Pathways / drug effects. Methotrexate / pharmacology. Neurotoxicity Syndromes. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2009 Jul;53(1):127; author reply 127-8 [19340855.001]
  • (PMID = 19006245.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


36. Högler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G: Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer; 2007 Jan;48(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database.
  • BACKGROUND: Skeletal complications during or after treatment of acute lymphoblastic leukemia (ALL) have been frequently reported and can cause substantial morbidity, yet their incidence is not well established.
  • PROCEDURE: Medical records of 122 ALL patients diagnosed at our institution from 1992 to 2004 were reviewed for information on fractures, ON, bone pain, and their anatomical location, risk group, phase of antileukemic therapy, and time since diagnosis.
  • Thirteen children were excluded as they were transferred to other institutions shortly after diagnosis.
  • Nearly all skeletal complications occurred during maintenance therapy at a median of 14.92 months (range 0.0-53.8) after diagnosis and in weight-bearing bones.
  • CONCLUSIONS: The doubled fracture rate and the high incidence of skeletal complications during the first years after diagnosis suggest the developing skeleton is very vulnerable in this period.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fractures, Bone / chemically induced. Fractures, Bone / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality


37. Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T, Bartkowiak J: Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma; 2005;52(4):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
  • Abnormalities of the P53 network have been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML).
  • To gain further insight into the role of P53 network in the evolution of acute leukemias, the P53, MDM2, BCL2 and BAX mRNAexpressions in portion samples from patients with ALL and AML were analyzed using multiplex RT-PCR.
  • A high frequency of BCL2 mRNA overexpression and a relatively low frequency of BAX mRNA overexpression detected in both analyzed leukemias in this study, indicate that altered transcription of these genes may be involved in leukemogenesis.
  • [MeSH-major] Gene Amplification. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059649.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


38. Spector LG, Xie Y, Robison LL, Heerema NA, Hilden JM, Lange B, Felix CA, Davies SM, Slavin J, Potter JD, Blair CK, Reaman GH, Ross JA: Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):651-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group.
  • BACKGROUND: The MLL 11q23 translocation arises in utero and is present in 75% of infant leukemias.
  • That MLL+ acute myeloid leukemia (AML) can arise following chemotherapy with DNA topoisomerase II (DNAt2) inhibitors suggests that these substances, which also occur naturally in foods, may contribute toward infant leukemia.
  • We hypothesized that maternal consumption of dietary DNAt2 inhibitors during pregnancy would increase the risk of infant leukemia, particularly AML(MLL+).
  • METHODS: This Children's Oncology Group case-control study consisted of 240 incident cases of infant acute leukemia [AML and acute lymphoblastic leukemia (ALL)] diagnosed during 1996 to 2002 and 255 random digit dialed controls.
  • RESULTS: There was little evidence of an association between the specific DNAt2 index and leukemia overall and by subtype.
  • For the vegetable and fruit index, there were significant or near-significant inverse linear trends for all leukemias combined, ALL(MLL+), and AML(MLL-).
  • CONCLUSION: Overall, maternal consumption of fresh vegetables and fruits during pregnancy was associated with a decreased risk of infant leukemia, particularly MLL+.
  • Although based on small numbers, these data provide some support for distinct etiologic pathways in infant leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767345.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA079940; United States / NCI NIH HHS / CA / CA79940
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase II Inhibitors
  •  go-up   go-down


39. Campana D: Role of minimal residual disease evaluation in leukemia therapy. Curr Hematol Malig Rep; 2008 Jul;3(3):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of minimal residual disease evaluation in leukemia therapy.
  • In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment.
  • Many studies in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia have demonstrated a strong association between the presence of MRD and risk of relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Flow Cytometry. Genes, T-Cell Receptor. Humans. Immunophenotyping. Neoplasm, Residual. Polymerase Chain Reaction. Prognosis. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Blood. 2000 Feb 1;95(3):815-9 [10648391.001]
  • [Cites] Leukemia. 2002 Mar;16(3):368-75 [11896540.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Blood. 2003 Jul 15;102(2):773-4; author reply 774 [12835231.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2387-92 [12239146.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):146-55 [16491074.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;313:145-56 [17217043.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1072-80 [11455976.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2115-20 [11264179.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2158-60 [15917380.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):243-52 [14531905.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1746-51 [11535507.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1783-9 [16838027.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2178-82 [14576731.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Blood. 2003 Jan 1;101(1):64-70 [12393605.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):849-51 [14520434.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • (PMID = 20425460.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115422; United States / NCI NIH HHS / CA / CA115422; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA60419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


40. Pei SN, Kuo CY, Ma MC, Wang MC: Mediastinal mass and malignant pleural effusion in an aleukemic case with pre-B acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Feb;31(2):139-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal mass and malignant pleural effusion in an aleukemic case with pre-B acute lymphoblastic leukemia.
  • After a bone marrow examination, we diagnosed the patient with pre-B acute lymphoblastic leukemia (ALL).
  • This is the first reported case of a malignant pleural effusion and a mediastinal mass that preceded pre-B ALL.
  • After standard therapy for ALL, the patient has been disease-free for 7 years.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Disease-Free Survival. Humans. Immunophenotyping. Male. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194202.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Ambati S, Chamyan G, Restrepo R, Escalon E, Fort J, Pefkarou A, Khatib ZA, Dehner LP: Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):433-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia.
  • A child with acute pre-B cell lymphoblastic leukemia underwent haploidentical bone marrow transplantation (BMT) after first relapse.
  • A biopsy of the presenting lesion demonstrated a polymorphous infiltrate composed predominantly of S-100 protein and CD68 immunoreactive histiocytic cells.
  • Together with the presence of emperipolesis, the process was interpreted as Rosai-Dorfman (R-D) disease.
  • Only one previous example of acute lymphoblastic leukemia in childhood has been reported with R-D disease.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Histiocytosis, Sinus / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


47. Dawidowska M, Wachowiak J, Witt M: [Molecular methods for diagnostics and assessment of treatment effectiveness in modern pediatric hematooncology]. Postepy Biochem; 2006;52(4):408-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper is a review of current diagnostic applications of molecular methods in pediatric hematooncology, including analyses performed at disease presentation, evaluation of prognosis as well as those for assessment of treatment effectiveness.
  • Here we present the examples of important fields of application of molecular methods in pediatric hematooncology, i.e. identification of clinically significant fusion genes in acute lymphoblastic leukemia and monitoring of minimal residual disease in this most frequent childhood malignancy.
  • Moreover, we present the methodology and clinical significance of quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / standards. Neoplasm, Residual / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Chimera / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536510.001).
  • [ISSN] 0032-5422
  • [Journal-full-title] Postepy biochemii
  • [ISO-abbreviation] Postepy Biochem.
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 41
  •  go-up   go-down


48. Shaheen SP 2nd, Talwalkar SS, Simons R, Yam L: Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature. Arch Pathol Lab Med; 2005 Jan;129(1):96-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature.
  • Leukemic transformation of chronic idiopathic myelofibrosis (CIMF) to acute lymphoblastic leukemia (ALL) is rare.
  • We report a case of a patient with CIMF who developed paroxysmal nocturnal hemoglobinuria (PNH) 2 years after initial presentation.
  • His disease eventually transformed to ALL of precursor B-cell type.
  • In that CIMF and PNH are clonal stem cell disorders with different pathogeneses, there may be an association between them.
  • The simultaneous presentation of CIMF and PNH, complicated by the rare sequela of leukemic transformation, raises important issues with regard to diagnosis and treatment.
  • [MeSH-major] Hemoglobinuria, Paroxysmal / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Primary Myelofibrosis / complications
  • [MeSH-minor] Chronic Disease. Humans. Male. Middle Aged


49. Thomson KJ, Mackinnon S: Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia. Curr Opin Hematol; 2006 Jul;13(4):273-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia.
  • Exploring the potential of allogeneic transplantation to eradicate disease has therefore been of interest for some time.
  • This review reports on recent developments in this field to evaluate the current status of stem cell transplantation in the management of these conditions.
  • RECENT FINDINGS: Most recent studies examine the application of reduced intensity regimens in follicular non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
  • Furthermore, the discovery of molecular/genetic factors that permit identification of patients with poor prognosis chronic lymphocytic leukemia has led to interest in identifying whether the allogeneic effect can overcome the impact of these factors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Graft vs Leukemia Effect. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphocyte Transfusion. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755225.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


50. Yadav KS, Sawant KK: Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv; 2010 Jan;7(1):51-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etoposide is one of the most commonly used drugs in chemotherapy of acute lymphocytic leukemia and acute myelogenous leukaemia.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044908.001).
  • [ISSN] 1875-5704
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / polylactic acid-polyglycolic acid copolymer; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 28
  •  go-up   go-down


51. Vormoor HJ: Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited. Cell Cycle; 2009 Apr 1;8(7):996-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited.
  • We have recently shown that in childhood acute lymphoblastic leukemia (ALL) blasts at different stages of immunophenotypic maturation possess stem cell properties.
  • Leukemia-propagating stem cells in ALL may be more frequent than previously thought!
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplastic Stem Cells / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19270513.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD34
  •  go-up   go-down


52. Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RA: Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res; 2007 Feb 15;67(4):1461-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
  • In T-cell acute lymphoblastic leukemia, alternative t(5;14)(q35;q32.2) forms effect dysregulation of either TLX3 or NKX2-5 homeobox genes at 5q35 by juxtaposition with 14q32.2 breakpoints dispersed across the BCL11B downstream genomic desert.
  • Leukemic gene dysregulation by t(5;14) was investigated by DNA inhibitory treatments with 26-mer double-stranded DNA oligonucleotides directed against candidate enhancers at, or near, orphan T-cell DNase I hypersensitive sites located between 3'-BCL11B and VRK1.
  • We suggest that HMGA1 and PU.1 coregulate ectopic homeobox gene expression in t(5;14) T-cell acute lymphoblastic leukemia by interactions mediated at the nuclear matrix.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Expression Regulation, Leukemic. HMGA Proteins / genetics. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Oncogene Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics. Trans-Activators / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308084.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL11B protein, human; 0 / DNA-Binding Proteins; 0 / HMGA Proteins; 0 / Histones; 0 / Homeodomain Proteins; 0 / NKX2-5 protein, human; 0 / Oligonucleotides; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / TLX3 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / proto-oncogene protein Spi-1; EC 3.1.21.1 / Deoxyribonuclease I
  •  go-up   go-down


53. Fulcher JW, Allred TJ, Kulharya A, Satya-Prakash KL, Seigler M, Neibarger D, Mazzella FM: Granular acute lymphoblastic leukemia in adults: report of a case and review of the literature. South Med J; 2006 Aug;99(8):894-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular acute lymphoblastic leukemia in adults: report of a case and review of the literature.
  • The diagnosis of granular acute lymphoblastic leukemia (ALL) can be problematic as the cytoplasmic granules found in many blast cells may mimic those seen in acute myelogenous leukemia (AML).
  • This rare variant of B-cell ALL is more commonly diagnosed in children, but may occur in adults.
  • [MeSH-major] Bone Marrow Cells / pathology. Cytoplasmic Granules / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Flow Cytometry. Humans. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929890.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Agueli C, Cammarata G, Salemi D, Dagnino L, Nicoletti R, La Rosa M, Messana F, Marfia A, Bica MG, Coniglio ML, Pagano M, Fabbiano F, Santoro A: 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. Am J Hematol; 2010 Aug;85(8):575-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a.
  • This study evaluated the loss and expression level of miRNAs 14q32 clusters in acute lymphoblastic leukemia (ALL) patients with cryptic deletions at 14q32 chromosomal band to investigate their involvement in this disease.
  • As a consequence of miRNAs deregulation we reported an inverse correlation with the expression of their target BCL11a, a transcription factor involved in lymphoid differentiation.
  • These results suggest that 14q32/miRNA clusters LOH may be another mechanism involved in lymphoid B cell transformation and differentiation and therefore, could be used as a diagnostic marker and therapeutic target in subsets of ALL.
  • [MeSH-major] Carrier Proteins / biosynthesis. Chromosomes, Human, Pair 14 / genetics. Gene Expression Regulation, Leukemic / genetics. Loss of Heterozygosity. MicroRNAs / genetics. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Neoplasm / genetics. Sequence Deletion
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Differentiation / genetics. Cell Transformation, Neoplastic / genetics. Child. Female. Humans. Male. Middle Aged. Up-Regulation. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20578197.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL11A protein, human; 0 / Carrier Proteins; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


55. Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, Rivera-Ramírez AB, Terán-Porcayo MA, Alarcón-Romero Ldel C, Illades-Aguiar B, Leyva-Vázquez MA: Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res; 2010 Jun;34(6):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico.
  • This study evaluated the association of -401C/T and +452C/T polymorphisms of gamma-glutamyl hydrolase and the risk of relapse to acute lymphoblastic leukemia.
  • Genotyping was performed in 70 children with acute lymphoblastic leukemia and 140 healthy children.
  • An association between the -401C/T polymorphism and the risk of relapse was found (p=0.028), patients with the -401T/T genotype have 10.83 (95% CI 1.30-90.14) more chance of a relapse of leukemia.
  • Therefore, our investigation suggests that the -401C/T polymorphism in the gamma-glutamyl hydrolase may be a factor involved in the generation of relapse to disease in patients with ALL.
  • [MeSH-major] Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. gamma-Glutamyl Hydrolase / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20197200.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM: Adult acute lymphoblastic leukemia: concepts and strategies. Cancer; 2010 Mar 01;116(5):1165-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia: concepts and strategies.
  • Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued.
  • Although ALL is a success story in pediatric oncology, results in adults lag behind those in children.
  • An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Chromosome Aberrations. Hematopoietic Stem Cell Transplantation. Humans. Philadelphia Chromosome. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Curr Opin Pediatr. 2008 Feb;20(1):17-22 [18197034.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Blood. 2007 May 1;109(9):3676-8 [17213285.001]
  • [Cites] Blood. 2007 Apr 1;109 (7):2744-50 [17132721.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1634-7 [17363514.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1643-50 [10029593.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):7-10 [19147069.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(7):635-42 [18084335.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1267-88 [11147223.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3768-73 [9850020.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4164-7 [17264295.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6341-8 [15322509.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):911-8 [19124805.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2097-101 [18720356.001]
  • [Cites] Bone Marrow Transplant. 1994 Sep;14(3):383-8 [7994259.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10 ):1293-302 [14499708.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):11-6 [19147070.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2007 Jan 15;109(2):683-92 [17008550.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14 (6):1327-52 [11147226.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):741-56 [12617874.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1615-6 [19228927.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1689-98 [19001083.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):254-61 [16421910.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):552-9 [15295048.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1316-22 [19164206.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):24-32 [19100365.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):748-54 [12181041.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2284-9 [19020309.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4153-62 [19141862.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):467-75 [16892073.001]
  • [Cites] Ann Intern Med. 1991 Jul 1;115(1):13-8 [2048858.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3072-8 [15637138.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Eur J Haematol. 2006 Dec;77(6):471-9 [16978239.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1646-54 [18502832.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Sep;13(9):1083-94 [17697971.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1269-82 [17613754.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):64-75 [19100369.001]
  • (PMID = 20101737.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


57. Zunino SJ, Storms DH, Ducore JM: Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett; 2010 Oct 1;296(1):49-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).
  • Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse.
  • Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Leuk Lymphoma. 2005 May;46(5):681-91 [16019505.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7 [19034447.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4100-8 [12010813.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Dec 30;141(3):956-62 [2880583.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):393-8 [2891436.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1597-600 [2595371.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3658-61 [8101765.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):275-83 [8199015.001]
  • [Cites] Blood. 1996 May 1;87(9):3892-8 [8611717.001]
  • [Cites] Leukemia. 1996 Mar;10(3):558-63 [8642875.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1135-46 [8695830.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4332-7 [8813118.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2015-9 [9292537.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Crit Rev Clin Lab Sci. 1998 Feb;35(1):1-57 [9532418.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):875-93 [17671794.001]
  • (PMID = 20381955.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA122117; United States / NCI NIH HHS / CA / 1R21CA122117-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  • [Other-IDs] NLM/ NIHMS195255; NLM/ PMC2906616
  •  go-up   go-down


58. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • [Transliterated title] Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes.
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • CONCLUSIONS: Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


59. Bandyopadhyay S, Bhattacharyya A, Mallick A, Sen AK, Tripathi G, Das T, Sa G, Bhattacharya DK, Mandal C: Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia. Int Immunol; 2005 Feb;17(2):177-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia.
  • Earlier studies have demonstrated an over-expression of 9-O-acetylated sialoglycoconjugates (9-OAcSGs) on lymphoblasts, concomitant with high titers of anti-9-OAcSGs in childhood acute lymphoblastic leukemia (ALL).
  • The present study was aimed to evaluate whether this high induction of anti-9-OAcSGs at disease presentation contributes toward immune surveillance.
  • Analysis of glycosylation of anti-9-OAcSGs purified from sera of ALL patients (IgG(ALL)) and normal individuals (IgG(N)) by digoxigenin glycan enzyme assay, fluorimetric estimation, gas-liquid chromatography and lectin-binding assays demonstrated that disease-specific antibodies differ in content and nature as compared with normal controls.
  • Enhanced amount of 9-OAcSA-specific IgG2 induced in ALL was unable to trigger activation of FcgammaR, the complement cascade and cell-mediated cytotoxicity, although its glycotope-binding ability remains unaffected.
  • Interestingly, only IgG1N emerged as the potent mediator of cell-mediated cytotoxicity, complement fixation and activator of effector cells through FcgammaR.
  • In ALL, the observed subclass switching of anti-9-OAcSGs to IgG2, alteration in their glycosylation profile along with impairment of a few Fc-glycosylation-sensitive effector functions hints toward a disbalanced homeostasis, thereby evading the host defense.
  • [MeSH-major] Glycoconjugates / immunology. Immunoglobulin G / blood. Immunoglobulin G / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Sialic Acids / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629900.001).
  • [ISSN] 0953-8178
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoconjugates; 0 / Immunoglobulin G; 0 / Receptors, Fc; 0 / Sialic Acids
  •  go-up   go-down


60. Ye Q, Wang ZH, Qin SK: [Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id]. Ai Zheng; 2008 Feb;27(2):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id].
  • BACKGROUND & OBJECTIVE: Idiotypic determinant (Id) of malignant B lymphocyte surface membrane immunoglobulin (SmIg) is not only a specific marker for chronic B-cell lymphatic leukemia (B-CLL) but also a specific antigen as an attractive target for active immunotherapy.
  • Killing efficiency of activated PBMCs to chronic B-cell leukemia cell line Daudi, chronic myelogenous leukemia cell line K562 and hepatoma carcinoma cell line HepG2 were tested by cell counting.
  • [MeSH-major] Antineoplastic Agents / pharmacology. HSP70 Heat-Shock Proteins / pharmacology. Immunoglobulin Idiotypes / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Single-Chain Antibodies / pharmacology
  • [MeSH-minor] Cell Proliferation / drug effects. Escherichia coli / genetics. Humans. Interleukin-12 / biosynthesis. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Recombinant Proteins / biosynthesis. Recombinant Proteins / isolation & purification. Recombinant Proteins / pharmacology. Tumor Necrosis Factor-alpha / biosynthesis

  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279608.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HSP70 Heat-Shock Proteins; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Proteins; 0 / Single-Chain Antibodies; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12
  •  go-up   go-down


61. Hourani R, Abboud M, Hourani M, Khalifeh H, Muwakkit S: L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics; 2008 Feb;39(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
  • L-asparaginase is a critical component in the treatment of acute lymphoblastic leukemia in children.
  • We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.
  • [MeSH-major] Asparaginase / adverse effects. Posterior Leukoencephalopathy Syndrome / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18504683.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


62. Ortuño FJ, Castilla C, Moreno MJ, del Mar Osma M, Gonzalez M, Vicente V: Erythrophagocytosis in de novo-philadelphia-positive acute leukemia of ambiguous lineage. Haematologica; 2006 Aug;91(8 Suppl):ECR43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrophagocytosis in de novo-philadelphia-positive acute leukemia of ambiguous lineage.
  • Erythrophagocytosis by neoplastic cells in acute leukemia has been most frequently associated with FAB M4 and M5 subtypes, with the t(8;16) and with C-MOZ rearrangements, however it is exceptional in acute lymphoblastic leukemia and has not been previously reported in Philadelphia-positive (Ph+) acute leukemia.
  • We herein present a case of Ph+ acute leukemia of ambiguous lineage in which erythrophagocytosis is an outstanding feature.
  • [MeSH-major] Erythrocytes / pathology. Leukemia / pathology. Philadelphia Chromosome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923527.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ: Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood; 2007 Sep 15;110(6):1924-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
  • To determine whether the leukemia-associated Wilms tumor antigen (WT1) contributes to a graft-versus-leukemia (GVL) effect after allogeneic stem-cell transplantation (SCT) for acute lymphoblastic leukemia (ALL), we studied CD8(+) T-cell responses to WT1 in 10 human lymphocyte antigen (HLA)-A*0201-positive ALL patients during the early phase of immune recovery after SCT (days 30-120).
  • Using WT1/HLA-A*0201 tetramers and intracellular interferon-gamma (IFN-gamma) staining, WT1(+) CD8(+) T-cell responses after SCT were found only in patients with detectable WT1 expression before SCT (5 of 7 vs. 0 of 3; P < .05).
  • To monitor the kinetics of WT1(+) CD8(+) T-cell responses and disease regression after SCT, absolute WT1(+) CD8(+) T-cell numbers and WT1 expression were studied for each time point.
  • Loss of WT1(+) CD8(+) T-cell responses was associated with reappearance of WT1 transcripts, consistent with a molecular relapse (P < .001).
  • [MeSH-major] Burkitt Lymphoma / therapy. Graft vs Leukemia Effect. Immunologic Memory. Stem Cell Transplantation. T-Lymphocytes / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. CD8-Positive T-Lymphocytes. Child. Cytomegalovirus / pathogenicity. Cytomegalovirus Infections / immunology. Cytomegalovirus Infections / therapy. Cytomegalovirus Infections / virology. Female. Graft vs Host Disease. HLA-A Antigens / metabolism. HLA-A2 Antigen. Humans. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Donors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 May 15;174(10):6088-94 [15879103.001]
  • [Cites] Immunity. 1999 Aug;11(2):183-90 [10485653.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2807-14 [10679124.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] J Clin Immunol. 2000 May;20(3):195-202 [10941827.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1480-9 [10942395.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2458-64 [10946271.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3126-32 [11049993.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):549-56 [10952724.001]
  • [Cites] Leukemia. 2001 Feb;15(2):293-302 [11236950.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):761s-765s [11300470.001]
  • [Cites] Methods Mol Med. 2002;68:223-37 [11901505.001]
  • [Cites] Cytotherapy. 2002;4(1):29-40 [11953039.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5455-64 [12023339.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):8210-8 [15944330.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):1014-21 [16338624.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):56-65 [16371020.001]
  • [Cites] Blood. 2006 Jan 1;107(1):205-12 [16144796.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Clin Immunol. 2006 Aug;120(2):121-8 [16766227.001]
  • [Cites] Cytotherapy. 2007;9(3):245-51 [17464756.001]
  • [Cites] Acta Haematol. 1999;102(2):72-6 [10529509.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1873-80 [10657636.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):783-8 [12732885.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1988-95 [12743153.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):56-61 [12894852.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Jan;18(1):165-6 [14603333.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):91-105 [14750075.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Jan;10(1):49-57 [14752779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(8):839-46 [14767500.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):590-600 [15147374.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):481-8 [15160909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2794-800 [15226184.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2195-204 [8630379.001]
  • [Cites] Blood. 2005 Jan 15;105(2):865-73 [15280205.001]
  • [Cites] Leukemia. 2005 Feb;19(2):268-74 [15538407.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3771-81 [8706023.001]
  • [Cites] Science. 1996 Oct 4;274(5284):94-6 [8810254.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):560-5 [8992968.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1751-67 [9292508.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1407-18 [9348298.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2197-207 [9490709.001]
  • [Cites] Nat Med. 1999 Jul;5(7):839-42 [10395333.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6571-6 [15905493.001]
  • (PMID = 17505014.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501963
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC1976363
  •  go-up   go-down


64. Yang H, Zhang C, Zhao X, Wu Q, Fu X, Yu B, Shao Y, Guan M, Zhang W, Wan J, Huang X: Analysis of copy number variations of BS69 in multiple types of hematological malignancies. Ann Hematol; 2010 Oct;89(10):959-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent array-based study implicated the presence of copy number variations (CNVs) of BS69 in the genomes of acute myelogenous leukemia.
  • CNVs are present in the general population at varying degrees and have been found to associate with various types of diseases including hematological malignancies.
  • We found significant association between the CNVs of BS69 and these hematological malignancies including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma (MM), and myelodysplastic syndrome (MDS).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425112.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / RNA, Messenger; 0 / ZMYND11 protein, human
  •  go-up   go-down


65. Shivarov V, Stoimenov A, Galabova I, Balatzenko G, Guenova M: Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia. Int J Lab Hematol; 2009 Feb;31(1):106-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia.
  • We report on a case of a 30-year-old male with acute B-lymphoblastic leukemia (B-ALL) with immunophenotype CD19(+), CD22(+), CD20(+), CD10(+), with aberrant expression of CD13 and CD117, and IgH gene rearrangements.
  • The case is the first report of a very early emergence of myeloid leukemia during the induction treatment for B-ALL in an adult patient.
  • Different pathogenetic mechanisms are discussed - clonal evolution or selection, lineage switch or development of a de novo or therapy-induced leukemia.
  • [MeSH-major] Leukemia, B-Cell / complications. Leukemia, Myeloid, Acute / complications


66. Stachel D, Albert M, Meilbeck R, Paulides M, Schmid I: Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia. Oncol Rep; 2007 Jan;17(1):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
  • Pathological angiogenesis is increasingly recognized to be an important feature of pathogenesis in solid tumors and also in leukemias.
  • Vascular endothelial growth factor (VEGF) seems to play a central role in tumor angiogenesis and is associated with a poor prognosis in both solid tumors and adult leukemias.
  • In pediatric acute lymphocytic leukemia however, the expression of angiogenic molecules and its relation to prognosis and relapse are unknown.
  • Therefore, we prospectively analyzed 46 pediatric patients with precursor B cell acute lymphocytic leukemia by semi-quantitative RT-PCR for expression of the angiogenic molecules VEGF, VEGF-C, iNOS and TGF-beta and correlated relapse and survival data with the expression of these factors.
  • A significantly higher mRNA expression of iNOS was found in surviving patients compared with non-surviving patients (p=0.023).
  • Angiogenic factors are expressed in the bone marrow of patients with pediatric B cell precursor ALL and VEGF is a potential candidate for therapeutic intervention as it is significantly higher expressed in children with late relapses.
  • The mRNA expression of iNOS in the surviving children possibly reflects an increased activity of the immune system against the leukemia which leads to a superior survival.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Burkitt Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143492.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


67. Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, Dörken B, Arnold R: A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica; 2010 May;95(5):810-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.
  • BACKGROUND: Disease stage is the most important prognostic parameter in allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia, but other factors such as donor/host histocompatibility and gender combination, recipient age, performance status and comorbidities need to be considered.
  • Several scoring systems are available to predict outcome in HCT recipients; however, their prognostic relevance in acute lymphoblastic leukemia is not well defined.
  • DESIGN AND METHODS: In the present study we evaluated a modified EBMT risk score (mEBMT) and the HCT-specific comorbidity index (HCT-CI) in 151 adult acute lymphoblastic leukemia patients who received allogeneic HCT from 1995 until 2007 at our center.
  • RESULTS: Disease status was first complete remission (CR1) (47%), CR>1 (21%) or no CR (32%).
  • Overall survival (OS) at one, two and five years was 62%, 51% and 40% and non-relapse mortality (NRM) was 21%, 24% and 32%.
  • Disease stage was the predominant prognostic factor in this score.
  • Comorbidities were present in 71% of patients with mild hepatic disease (29%), moderate pulmonary disease (28%) and infections (23%) being the most common.
  • However, KPS was associated with disease stage and significance was lost in multivariate analysis.
  • CONCLUSIONS: The mEBMT was prognostic in our patient cohort with predominant influence of disease stage, whereas a trend but no significant prognostic value was observed for the HCT-CI.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / standards. Karnofsky Performance Status / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Preoperative Care / standards. Transplantation Conditioning / standards

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2003 Jul;9(7):472-81 [12869961.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Bone Marrow Transplant. 1996 Jan;17(1):13-8 [8673048.001]
  • [Cites] Lancet. 1998 Oct 3;352(9134):1087-92 [9798583.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):407-14 [16549853.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):201-9 [16939494.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41 [17640597.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):381-7 [17563735.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4246-54 [17724349.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507 [18022580.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4606-13 [17873123.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35 [18158958.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(8):721-7 [18176613.001]
  • [Cites] Cancer. 2008 May 1;112(9):1992-2001 [18311781.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):805-12 [18195682.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9):985-92 [18721761.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5585-93 [18765552.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25 [18940675.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):395-403 [18759762.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2062-9 [18685612.001]
  • [Cites] Eur J Clin Invest. 2008 Dec;38(12):945-52 [19021720.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):149-53 [19147097.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):223-30 [19167682.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(2):133-9 [18762762.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1131-8 [19194465.001]
  • [Cites] Curr Hematol Malig Rep. 2009 Jul;4(3):139-47 [20425427.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1596-9 [12886248.001]
  • (PMID = 20007143.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864388
  •  go-up   go-down


68. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC: CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood; 2010 Feb 11;115(6):1204-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
  • CD19 is a B cell-specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies.
  • The NK cell-mediated cytolytic and secretory function with XmAb5574 compared with the nonengineered antibody is associated with enhanced NK-cell activation, interferon production, extracellular signal-regulated kinase phosphorylation downstream of Fcgamma receptor, and no increased NK-cell apoptosis.
  • Notably, enhanced NK cell-mediated ADCC with XmAb5574 was enhanced further by lenalidomide.
  • These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Oct 1;110(7):2569-77 [17440052.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55 [17671129.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):46-58 [17991300.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4173-83 [18174382.001]
  • [Cites] Nat Immunol. 2008 May;9(5):503-10 [18425107.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8049-57 [18829563.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5180-9 [18772452.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3735-43 [19109559.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4352-61 [19147785.001]
  • [Cites] Blood. 2011 Apr 28;117(17):4530-41 [21228331.001]
  • [Cites] Immunol Res. 2000;22(2-3):281-98 [11339363.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):649-54 [11697493.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):983-92 [12370276.001]
  • [Cites] J Cell Biochem. 2003 May 15;89(2):279-88 [12704791.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1846-54 [14630799.001]
  • [Cites] Ann Hematol. 2004 Oct;83(10):634-45 [15309525.001]
  • [Cites] J Exp Med. 1988 Feb 1;167(2):408-20 [2964496.001]
  • [Cites] Clin Immunol Immunopathol. 1988 May;47(2):219-29 [3258212.001]
  • [Cites] J Exp Med. 1990 Apr 1;171(4):1333-45 [2139103.001]
  • [Cites] Cancer Immunol Immunother. 1991;32(6):364-72 [1706642.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1390-7 [8118040.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):840-6 [7531616.001]
  • [Cites] Immunity. 1995 Jul;3(1):39-50 [7542548.001]
  • [Cites] Nature. 1995 Jul 27;376(6538):352-5 [7543183.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S192-8 [17877844.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11558-62 [8524803.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4389-99 [8541526.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Immunol. 1996 Jul 1;157(1):48-56 [8683154.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1027-35 [9064320.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3062-9 [9120258.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3148-54 [9120268.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4662-9 [9144478.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3278-87 [9317126.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3804-16 [9808574.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6648-56 [9862693.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):87-100 [15621786.001]
  • [Cites] Leukemia. 2005 May;19(5):835-40 [15744340.001]
  • [Cites] Leukemia. 2006 Feb;20(2):272-9 [16341049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 [16537476.001]
  • [Cites] J Clin Invest. 2006 Sep;116(9):2484-92 [16917543.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Apr;62(1):26-33 [17240158.001]
  • [Cites] Nat Med. 2007 May;13(5):587-96 [17435771.001]
  • [Cites] Adv Immunol. 2007;96:41-101 [17981204.001]
  • (PMID = 19965644.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01 CA81534; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / P01 CA095426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Immunoglobulin Fc Fragments; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2826232
  •  go-up   go-down


69. Tedeschi A, Vismara E, Ricci F, Morra E, Montillo M: The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther; 2010;3:227-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of use of rituximab in chronic lymphocytic leukemia.
  • The monoclonal chimeric anti-CD20 antibody, rituximab, has considerably improved therapeutic outcome in B-cell chronic lymphocytic leukemia.
  • Furthermore the addition of rituximab enabled the eradication of minimal residual disease, which is correlated with the prognosis in a high proportion of patients.
  • Although the role of rituximab as maintenance therapy in low grade non-Hodgkin's lymphomas has been determined, the benefit and optimal schedule in chronic lymphocytic leukemia are still under investigation.
  • This review brings together knowledge of the pharmacokinetics, mechanism of action and clinical use of rituximab in chronic lymphocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Br J Haematol. 2001 Aug;114(2):342-8 [11529853.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] Hematol J. 2001;2(5):300-6 [11920265.001]
  • [Cites] Hematol J. 2002;3(1):7-9 [11960388.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] J Clin Immunol. 2002 May;22(3):124-30 [12078853.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):767-72 [12153163.001]
  • [Cites] Haematologica. 2002 Sep;87(9):918-25 [12217803.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):976-84 [12472576.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 2):34-9 [12652463.001]
  • [Cites] Int J Clin Oncol. 2003 Aug;8(4):212-23 [12955576.001]
  • [Cites] Ann Hematol. 2003 Dec;82(12):759-65 [14551737.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2269-73 [15512816.001]
  • [Cites] Curr Dir Autoimmun. 2005;8:140-74 [15564720.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2965-72 [12351409.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3115-20 [12384407.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Eur J Haematol. 2002 Sep;69(3):129-34 [12406005.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2507-13 [12446458.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1278-84 [12663715.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):945-50 [15291353.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2971-9 [15738539.001]
  • [Cites] Haematologica. 2005 Mar;90(3):391-9 [15749671.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):337-45 [16353201.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):377-89 [16793209.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Leukemia. 2007 Jan;21(1):12-7 [17109028.001]
  • [Cites] Leuk Lymphoma. 2007 May;48(5):905-11 [17487734.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2291-8 [17514743.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):107-13 [17635235.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Mol Immunol. 2007 Sep;44(16):3823-37 [17768100.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):119-28 [17999417.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):196-203 [18182662.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 May 15;111(10):4916-21 [18309034.001]
  • [Cites] Haematologica. 2008 Mar;93(3):475-6 [18310545.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1017-29 [18358929.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2048-53 [18754025.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2110-8 [18759253.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1995-8 [18949622.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):498-503 [19075274.001]
  • [Cites] Cancer. 2010 May 15;116(10):2360-5 [20225334.001]
  • [Cites] Leuk Lymphoma. 2010 Aug;51(8):1485-93 [20578816.001]
  • [Cites] Expert Rev Hematol. 2010 Apr;3(2):131-48 [21083456.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):364-9 [9708202.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):57-65 [10613450.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Leuk Res. 2000 May;24(5):411-5 [10785263.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Blood. 2000 Jul 1;96(1):71-5 [10891432.001]
  • [Cites] Acta Haematol. 1989;81(4):181-5 [2502891.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):167-70 [10350345.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):800-9 [11564066.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1619-26 [11587221.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):491-7 [19075280.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):373-80 [19117034.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):514-6 [19347738.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2044-50 [19553638.001]
  • [Cites] Leuk Res. 2010 Mar;34(3):284-8 [19646755.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1779-89 [19693094.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4578-84 [19704063.001]
  • [Cites] Blood. 2010 Jan 21;115(3):489-95 [19843887.001]
  • [Cites] Leuk Lymphoma. 2010 Jan;51(1):107-13 [20001234.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:440-9 [20008230.001]
  • [Cites] Cancer. 2010 May 1;116(9):2180-7 [20187101.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1756-65 [20194844.001]
  • (PMID = 21289858.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3024887
  • [Keywords] NOTNLM ; B-cell chronic lymphocytic leukemia / first-line treatment / refractory/relapsed / rituximab
  •  go-up   go-down


70. Yang Y, Tian Y, Yan C, Jin X, Tang J, Shen X: Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia. Environ Toxicol; 2009 Oct;24(5):446-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia.
  • The 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidized nucleoside of DNA, not only is a widely used biomarker for the measurement of endogenous oxidative DNA damage, but might also be a risk factor for many diseases including cancer.
  • In the present study, the level of urinary 8-OHdG was examined in 116 Chinese children with acute leukemia (94 acute lymphoid leukemia, ALL, 22 acute myeloid leukemia, AML), and its correlation with urinary metal elements was investigated.
  • Our result showed that the level of urinary 8-OHdG in children with acute leukemia before treatment was significantly elevated compared with that in normal controls (11.92 +/- 15.42 vs. 4.03 +/- 4.70 ng/mg creatinine, P < 0.05).
  • In particular, urinary 8-OHdG was higher in children with acute leukemia aged under 3 years (20.86 +/- 21.75 ng/mg creatinine) than in those aged 3-15 years (8.09 +/- 9.65 ng/mg creatinine), whereas no differences were shown in terms of gender, parental smoking and education, household income, place of residence, and use of paracetamol.
  • In addition, urinary 8-OHdG levels were similar among different subtypes of acute lymphoid leukemia (ALL) patients.
  • Furthermore, linear regression analysis revealed a significant correlation between urinary 8-OHdG and urinary Cr, but not Fe or As, in group aged <3 years compared with group aged 3-15 years (P = 0.041), indicating that the metal elements may be involved in increasing urinary 8-OHdG level in younger children with acute leukemia.
  • Our results suggest that children with acute leukemia undergo an increased risk of oxidative DNA damage, which may be correlated with high level of Cr exposure in Chinese children with acute leukemia.
  • [MeSH-major] Carcinogens / metabolism. Deoxyguanosine / analogs & derivatives. Leukemia, Myeloid, Acute / urine. Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979530.001).
  • [ISSN] 1522-7278
  • [Journal-full-title] Environmental toxicology
  • [ISO-abbreviation] Environ. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Metals; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


71. Gelfand MS, Cleveland KO, Brewer SC: Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia. Am J Med Sci; 2010 Jul;340(1):80-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
  • Cavitary pneumonia caused by Rhodococcus equi may occur in patients with defective cell-mediated immunity.
  • Prolonged CD4 lymphopenia may develop in patients with chronic lymphocytic leukemia who receive fludarabine.
  • The authors report the first case of a patient with chronic lymphocytic leukemia who developed R equi pneumonia after fludarabine therapy.
  • [MeSH-major] Actinomycetales Infections / microbiology. Leukemia, Lymphoid / drug therapy. Lymphopenia / drug therapy. Pneumonia, Bacterial / microbiology. Rhodococcus equi / isolation & purification
  • [MeSH-minor] Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Bronchoalveolar Lavage Fluid / microbiology. CD4 Lymphocyte Count. Chronic Disease. Female. Humans. Opportunistic Infections / microbiology. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use


72. Saygili EI, Aksoy N, Pehlivan M, Sever T, Yilmaz M, Cimenci IG, Pehlivan S: Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma; 2009 Dec;50(12):2030-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma.
  • The aim of this study was to investigate how myeloperoxidase (MPO) G-463A gene polymorphism and enzyme levels varied among patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) and to find the relationship between the MPO gene, enzyme levels, and clinical parameters.
  • In accordance with the results of the study, we assess that the increase in the MPO enzyme level in the patient groups with CLL and MM generated bactericidal effects as well as the increased formation of ROP, thus setting off a pro-cell death pathway and playing a role on the pathogenesis of lymphoproliferative malignancies through this mechanism.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Multiple Myeloma / genetics. Peroxidase / genetics


73. Kalac M, Suvic-Krizanic V, Ostojic S, Kardum-Skelin I, Barsic B, Jaksica B: Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis. Int J Hematol; 2007 May;85(4):323-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis.
  • Leukemic involvement of the central nervous system (CNS) in previously undiagnosed chronic lymphocytic leukemia (CLL) is very rare.
  • We report the case of a 62-year-old man with neuroborreliosis in which cytologic, immunocytochemical, and flow cytometry analyses revealed the presence of clonal B-lymphocytes in the cerebrospinal fluid (CSF).
  • The application of intrathecal dexamethasone therapy led to the disappearance of B-cell CLL (B-CLL) cells in the CSF.
  • [MeSH-major] Central Nervous System / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / drug therapy. Leukemic Infiltration / pathology. Lyme Neuroborreliosis / drug therapy. Lyme Neuroborreliosis / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):311-9 [2306790.001]
  • [Cites] Postgrad Med J. 2005 Mar;81(953):194-5 [15749798.001]
  • [Cites] Expert Opin Pharmacother. 2001 Jun;2(6):929-43 [11585009.001]
  • [Cites] Eur J Intern Med. 2003 Feb;14(1):49-52 [12554011.001]
  • [Cites] J Neuroimmunol. 2000 Oct 2;110(1-2):244-51 [11024556.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):199-201 [11908730.001]
  • [Cites] Infect Immun. 2005 Feb;73(2):1014-22 [15664945.001]
  • [Cites] Br J Haematol. 1999 Mar;104(4):689-94 [10192427.001]
  • [Cites] Blood. 2000 Jul 15;96(2):776-7 [10950515.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):592-600 [9778257.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):1-8 [3342460.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):401-8 [9466528.001]
  • [Cites] Leukemia. 1996 May;10(5):877-95 [8656686.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):619-21 [16019494.001]
  • [Cites] Leuk Lymphoma. 1998 Feb;28(5-6):603-5 [9613992.001]
  • [Cites] J Clin Pathol. 1996 Aug;49(8):672-5 [8881921.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):402-4 [12185514.001]
  • [Cites] J Neuroophthalmol. 2005 Jun;25(2):113-5 [15937434.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1235-7 [12916878.001]
  • (PMID = 17483076.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; 7S5I7G3JQL / Dexamethasone; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


74. Schöttker B, Feuchtinger T, Schumm M, Klinker E, Handgretinger R, Einsele H, Stuhler G: Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors. Nat Clin Pract Oncol; 2008 May;5(5):291-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INVESTIGATIONS: Laboratory tests, immunophenotyping, cytogenetic analyses, bone-marrow biopsy, minimal residual disease analysis using quantitative real-time polymerase chain reaction, differential chimerism analysis using flow cytometry, mixed chimerism analysis, CT scans, electro-encephalography, cerebral magnetic resonance tomography.
  • DIAGNOSIS: Bcr-abl-positive and Philadelphia-chromosome-positive acute lymphoblastic leukemia, and primary graft failure complicated by invasive fungal infection and cytomegalovirus encephalitis.
  • MANAGEMENT: Double cord-blood rescue transplantation, third-party CD34-positive stem-cell rescue transplantation, third-party cytomegalovirus-specific T lymphocyte transplantation.
  • [MeSH-major] Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Cord Blood Stem Cell Transplantation. Granulocytes / transplantation. Humans. Killer Cells, Natural / transplantation. Male. Mosaicism. T-Lymphocytes / transplantation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364724.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Pettit GR, Thornhill AJ, Moser BR, Hogan F: Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug. J Nat Prod; 2008 Sep;71(9):1561-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both phenazines 7 and 11 significantly inhibited (ED50 approximately 0.2 microg/mL) growth of the murine P388 lymphocytic leukemia cell line and provided a new SAR insight in the combretastatin series of naturally occurring anticancer drugs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drug Des. 2000 Jun;15(3):203-16 [11049088.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1885-94 [17941699.001]
  • [Cites] Bioorg Med Chem. 2003 Jul 17;11(14):3179-91 [12818681.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):604-10 [15239140.001]
  • [Cites] J Nat Prod. 1987 Jan-Feb;50(1):119-31 [3598594.001]
  • [Cites] Experientia. 1989 Feb 15;45(2):209-11 [2920809.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(3):307-12 [2094431.001]
  • [Cites] Pharmacol Ther. 1993 Aug;59(2):163-228 [8278462.001]
  • [Cites] J Med Chem. 1995 May 12;38(10):1666-72 [7752190.001]
  • [Cites] Anticancer Drug Des. 1995 Jun;10(4):299-309 [7786396.001]
  • [Cites] Anticancer Drug Des. 1998 Apr;13(3):183-91 [9595032.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2992-3006 [16224539.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4090-4 [16818709.001]
  • [Cites] Bioorg Med Chem. 2007 Jan 15;15(2):605-15 [17070061.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Apr;16(4):451-65 [17371194.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):19-24 [18043252.001]
  • [Cites] Biosci Biotechnol Biochem. 2001 Dec;65(12):2613-21 [11826955.001]
  • (PMID = 18729517.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090441-05; United States / NCI NIH HHS / CA / R01 CA090441; United States / NCI NIH HHS / CA / R01 CA090441-01; United States / NCI NIH HHS / CA / R56 CA090441-06A1; United States / NCI NIH HHS / CA / R01 CA090441-02; United States / NCI NIH HHS / CA / 2R56 CA090441-06A1; United States / NCI NIH HHS / CA / R01 CA090441-04; United States / NCI NIH HHS / CA / R01 CA090441-03; United States / NCI NIH HHS / CA / R01 CA90441-01-05; United States / NCI NIH HHS / CA / R56 CA090441
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biological Products; 0 / Prodrugs; 0 / Quinones; 0 / Stilbenes; 109971-63-3 / combretastatin A-1; I5590ES2QZ / fosbretabulin
  • [Other-IDs] NLM/ NIHMS86312; NLM/ PMC2756244
  •  go-up   go-down


76. Uckun FM, Dibirdik I, Qazi S, Yiv S: Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Arzneimittelforschung; 2010;60(4):210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
  • Notably, WHI-P131-NP was capable of causing apoptotic death in primary leukemia cells from chemotherapy-resistant acute lymphoblastic leukemia (ALL) as well as chronic lymphocytic leukemia (CLL) patients.
  • These experimental results demonstrate that the nanotechnology-enabled delivery of WHI-P131 shows therapeutic potential against leukemias with constitutive activation of the JAK3-STAT3/STAT5 molecular target.
  • [MeSH-major] Antineoplastic Agents. Janus Kinase 3 / antagonists & inhibitors. Leukemia, B-Cell / drug therapy. Leukemia, Biphenotypic, Acute / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / pharmacology. Quinazolines / administration & dosage. Quinazolines / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Calibration. Cell Lineage. Chemistry, Pharmaceutical. Chromatography, High Pressure Liquid. Female. Humans. Liposomes. Mice. Mice, SCID. Nanoparticles. Osmolar Concentration. Particle Size

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arzneimittelforschung. 2010;60(5):286
  • (PMID = 20486472.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / WHI P131; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


77. Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E: High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol; 2007 May;59(6):771-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
  • OBJECTIVE: High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies.
  • PATIENTS AND METHODS: Twenty-five patients with refractory or relapsed acute lymphoblastic leukemia received Ara-C 3 g/m2 from days 1-5, idarubicin (HD-IDA) 40 mg/m2 as rapid intravenous (i.v.) infusion on day 3 and subcutaneous G-CSF 5 microg/kg from day 7 until PMN recovery.
  • RESULTS: Eleven patients (44%, 95% CI: 23-65%) achieved complete remission with median disease free survival for 6 months.
  • Our data do not allow us to clearly attribute this behavior to a pharmacokinetic non-linearity since the baseline creatinine clearance, even within normal values, and patient age are significantly different in the two groups.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recurrence. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256136.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


78. Sazawal S, Bakhshi S, Raina V, Swaroop C, Saxena R: Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases. J Pediatr Hematol Oncol; 2009 Nov;31(11):850-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases.
  • The bcr-abl rearrangement has rarely been reported in T-lineage acute lymphoblastic leukemia and the clinical significance of this translocation is currently unknown.
  • We screened 28 children with T-lineage acute lymphoblastic leukemia at diagnosis by reverse transcription polymerase chain reaction for major and minor break point regions of bcr-abl fusion gene.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 9 / genetics. Genes, abl / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic


79. Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, Penther D, Bastard C, Poppe B, Speleman F, Baranger L, Luquet I, Cornillet-Lefebvre P, Nadal N, Nguyen-Khac F, Pérot C, Olschwang S, Bertucci F, Chaffanet M, Lessard M, Mozziconacci MJ, Birnbaum D, Groupe Francophone de Cytogénétique Hématologique: Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia; 2009 Jan;23(1):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases.
  • The t(8;16)(p11;p13) is a rare translocation involved in de novo and therapy-related myelomonocytic and monocytic acute leukemia.
  • MYST3-linked acute myeloid leukemias (AMLs) share specific clinical and biological features and a poor prognosis.
  • We have established the genome and gene expression profiles of a multicentric series of 61 M4/M5 AMLs including 18 MYST3-linked AMLs by using array comparative genome hybridization (aCGH) (n=52) and DNA microarrays (n=44), respectively.
  • These features, reminiscent of T-cell acute lymphoid leukemia (ALL), suggest the targeting of a common T-myeloid progenitor.
  • [MeSH-major] Gene Expression Profiling / methods. Genes, myb / genetics. Histone Acetyltransferases / genetics. Leukemia, Myelomonocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818702.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins c-myb; 157907-48-7 / HoxA protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


80. Beyan C, Kaptan K, Ifran A: Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis. Ann Hematol; 2006 Nov;85(11):811-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis.
  • [MeSH-major] Hashimoto Disease / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845514.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


81. Qu L, Li Q, Jiang H, Gu L, Zhang Q, Wang C, Li J: Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes. Transplantation; 2009 Sep 27;88(6):766-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: CD52 monoclonal antibody (mAb) has been used therapeutically in lymphocytic leukemia, autoimmune disease, and organ transplantation.
  • [MeSH-minor] Animals. Antigens, CD. Antigens, Neoplasm. Apoptosis / immunology. Cell Survival / immunology. Epithelium / immunology. Epithelium / metabolism. Epithelium / pathology. Immunity, Mucosal. Injections, Subcutaneous. Lymphocyte Count. Lymphocyte Depletion / adverse effects. Male. Mice. Mice, Inbred C57BL. Permeability. Transplantation Immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920775.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


82. Milne E, Laurvick CL, de Klerk N, Robertson L, Thompson JR, Bower C: Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006. Int J Cancer; 2008 Mar 1;122(5):1130-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006.
  • Increases in the incidence of childhood acute lymphoblastic leukemia (ALL) have been reported in some countries, while other reports from similar geographical regions have indicated stable rates.
  • The reasons for the discrepancies have been debated in the literature, with the focus on whether the observed increases are "real" or an artifact resulting from improvements in diagnosis, case ascertainment and population coverage over time.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


83. Nabhan C: Frontline therapy for chronic lymphocytic leukemia: the dilemma continues. Clin Cancer Res; 2008 Jul 1;14(13):4353
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • (PMID = 18594019.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


84. Al'-Radi LS, Samoĭlova RS, Tikhonova LIu, Diagileva OA, Obukhova TN, Kaplanskaia IB, Gretsov EM, Vorob'ev IA, Kremenetskaia AM, Kravchenko SK: [Combination of chronic lymphoid leukemia and hairy cell leukemia]. Ter Arkh; 2006;78(7):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of chronic lymphoid leukemia and hairy cell leukemia].
  • [MeSH-major] Leukemia, Hairy Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944757.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


85. Aricò M, Conter V, Valsecchi MG, Rizzari C, Boccalatte MF, Barisone E, Messina C, De Rossi G, Lo Nigro L, Pession A, Locatelli F, Micalizzi C, Basso G: Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica; 2005 Sep;90(9):1186-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
  • BACKGROUND AND OBJECTIVES: Treatment of childhood standard-risk (SR) acute lymphoblastic leukemia (ALL) is generally successful.
  • DESIGN AND METHODS: The population of patients with SR ALL included children aged between 1 and 6 years with less than 20,000 WBC/mm3, non-T immunophenotype, DNA index between 1.16 and 1.6, absence of t(9;22) and t(4;11) clonal translocations, no extramedullary leukemia, good response to prednisone and complete remission (CR) at the end of induction therapy.
  • After a median follow-up of 5.9 years, 11 patients in the SR protocol had relapsed, 1 had died in remission, and 1 had developed a second malignant neoplasm.
  • Thus, alternative selection criteria, such as treatment response measured by minimal residual disease, should be considered to address the issue of treatment reduction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


86. Lazarevic V, Wahlin A, Hultdin M, Zhan F, Shaughnessy J: Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1. Leuk Lymphoma; 2006 Sep;47(9):1987-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.
  • [MeSH-major] Bone Diseases / diagnosis. Diagnosis, Differential. Intercellular Signaling Peptides and Proteins / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065022.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


87. Steinherz PG, Meyers PA, Steinherz LJ, Jeha S: Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol; 2007 Sep;29(9):656-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
  • Current treatments for relapsed/refractory leukemias are unable to achieve extended remissions in most patients even with multiagent chemotherapy.
  • Clofarabine is a new nucleoside analog that has demonstrated clinical benefit in phase I-II studies, and is currently being studied in children and adults with leukemias and has been approved for the treatment of children with relapsed or refractory acute lymphocytic leukemia.
  • We report the experience of three adolescents, two with acute lymphocytic leukemia in 3rd relapse and one with relapsed/refractory acute myeloid leukemia, who achieved complete remission with clofarabine.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Female. Humans. Male. Recurrence. Remission Induction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805046.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


88. Li Z, Li W, Meklat F, Wang Z, Zhang J, Zhang Y, Lim SH: A yeast two-hybrid system using Sp17 identified Ropporin as a novel cancer-testis antigen in hematologic malignancies. Int J Cancer; 2007 Oct 1;121(7):1507-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Applying Sperm protein 17 (Sp17) as the bait in a yeast 2-hybrid system of a testicular cDNA library, 17 interacting clones were isolated and all encoded Ropporin, a spermatogenic cell-specific protein that serves as an anchoring protein for the A-kinase anchoring protein, AKAP110.
  • Ropporin mRNA could also be detected in tumor cells from patients with multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551920.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 088434; United States / NCI NIH HHS / CA / R01 CA 106283
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / Immunoglobulin G; 0 / Membrane Proteins; 0 / ROPN1 protein, human; 0 / Recombinant Proteins; 0 / SPA17 protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


89. Kozlov I, Beason K, Yu C, Hughson M: CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet; 2005 Nov;163(1):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
  • Acute leukemias that express antigens associated with more than one lineage have been classified as acute lymphocytic leukemia with myeloid markers, acute myeloid leukemia with lymphoid markers, or biphenotypic acute leukemia (BAL).
  • CD79a functions in and has a high degree of specificity for B-cell differentiation.
  • It has only recently begun to be reported in biphenotypic acute leukemias.
  • Cases of acute leukemia submitted to the flow cytometry laboratory were retrospectively reviewed beginning from the time analysis for cytoplasmic CD79a was added to leukemia and lymphoma panels.
  • The immunophenotyping met proposed scoring criteria for a diagnosis of BAL.
  • Nevertheless, the cytogenetic and FISH findings indicate that CD79a, despite its specificity for B-cell differentiation, represented the aberrant presence of a B-cell antigen in leukemias of distinct myeloid linage.
  • [MeSH-major] Antigens, CD79 / genetics. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD / genetics. Antigens, CD / immunology. B-Lymphocytes / immunology. Blast Crisis. Bone Marrow Cells / pathology. Cytarabine / therapeutic use. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Genet Cytogenet. 2007 Apr 1;174(1):76-7 [17350472.001]
  • (PMID = 16271957.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD79; 04079A1RDZ / Cytarabine
  •  go-up   go-down


90. Zakharova AI, Obukhova TN, Lorie IuIu, Nikitin EA, Samoĭlova RS, Zingerman BV, Domracheva EV: [Cytogenetic disorders in chronic B-cell lymphoid leukemia and their relations with clinicobiological features and prognosis of the disease]. Ter Arkh; 2006;78(7):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic disorders in chronic B-cell lymphoid leukemia and their relations with clinicobiological features and prognosis of the disease].
  • AIM: To study a relationship between cytogenetic disorders, clinicobiological characteristics and prognosis in chronic B-cell lymphoid leukemia (B-CLL).
  • [MeSH-major] Chromosome Aberrations. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD38 / genetics. Bone Marrow / pathology. Disease-Free Survival. Female. Humans. Immunoglobulin Variable Region / genetics. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. Membrane Glycoproteins / genetics. Middle Aged. Neoplasm Staging. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944752.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region; 0 / Membrane Glycoproteins; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


91. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU: ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology; 2009 Aug;14(4):204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
  • Childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cells and chronic lymphocytic leukemia (CLL) cells of adults were studied.
  • No differences between expression of P-gp and BCRP and genes in primary and relapsed acute leukemia (AL) cells as well as in de novo and treated CLL samples were established.
  • A tendency for the decreased doxorubicin cytotoxic activity was shown in BCRP-overexpressing cells both in children and adults leukemia.
  • Multifactorial ANOVA showed that P-gp/MDR1 and BCRP as well as their function could not be used as unconditional and universal predictors of leukemia cell drug resistance in vitro.
  • These results suggest that studied MDR transporter-proteins have a limited role per se in vitro and admittedly in vivo drug resistance estimated in leukemia patients or it is not yet fully understood unless would not be studied in aggregate.
  • In any event, the expression and function studies of the proteins under investigation when singularly considered do not have a crucial significance for impact on drug resistance evaluation in all leukemia patients.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette, Sub-Family B, Member 1 / biosynthesis. Leukemia / drug therapy. Leukemia / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family B. ATP Binding Cassette Transporter, Sub-Family G, Member 2. Acute Disease. Adolescent. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Child, Preschool. Drug Resistance, Neoplasm. Gene Expression. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635183.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Neoplasm Proteins
  •  go-up   go-down


92. Evrard S, Gaussem P, Helley D, Darnige L: [Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers]. Ann Biol Clin (Paris); 2005 Nov-Dec;63(6):589-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers].
  • [Transliterated title] Facteurs pronostiques de la leucémie lymphoïde chronique: apport des marqueurs biologiques récents.
  • Chronic lymphocytic leukemia (CLL) is the most common lymphoid hemopathy in elderly.
  • Diagnosis of CLL is easily made with a full blood count and immunophenotyping, but there is an heterogeneity in clinical evolution.
  • In order to detect these patients, it is useful to have some relevant markers to predict disease evolution.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330377.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 41
  •  go-up   go-down


93. Lamanna N: Challenges in the frontline treatment of patients with chronic lymphocytic leukemia. Curr Hematol Malig Rep; 2010 Jan;5(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges in the frontline treatment of patients with chronic lymphocytic leukemia.
  • Therapy for chronic lymphocytic leukemia has improved dramatically over the past 20 years.
  • Though not yet demonstrated in a prospective randomized trial, treatment approaches aimed at achieving high-quality responses may one day improve survival for patients with chronic lymphocytic leukemia.
  • However, many challenges remain, such as finding less toxic and equally efficacious regimens for older patients, who remain the majority of the population with this disease.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Drugs, Investigational / administration & dosage. Forecasting. Hematopoietic Stem Cell Transplantation. Humans. Immunologic Factors / administration & dosage. Multicenter Studies as Topic. Prognosis. Remission Induction. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):457-9 [2464793.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2657-63 [14669286.001]
  • [Cites] Blood. 1992 Jul 1;80(1):29-36 [1377051.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Blood. 2006 Aug 1;108(3):853-61 [16601244.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1196-201 [2993534.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 1991 Oct 15;78(8):1901-14 [1912574.001]
  • [Cites] Blood. 1995 Jan 15;85(2):307-18 [7811987.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4378-84 [19652068.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1278-84 [12663715.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):433-8 [2784491.001]
  • [Cites] Immunology. 1998 Nov;95(3):427-36 [9824507.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):44-9 [1702145.001]
  • [Cites] Blood. 1989 Jul;74(1):19-25 [2473795.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1290-3 [8057664.001]
  • [Cites] Blood. 2009 Oct 15;114(16):3382-91 [19605849.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2723-9 [11023504.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):491-7 [19075280.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Leukemia. 1993 Mar;7(3):361-5 [7680398.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2291-8 [17514743.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1577-82 [10995003.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Blood. 2000 Jul 1;96(1):71-5 [10891432.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 20425396.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antimetabolites, Antineoplastic; 0 / Drugs, Investigational; 0 / Immunologic Factors
  • [Number-of-references] 57
  •  go-up   go-down


94. Suga A, Yamanishi Y, Hashimoto K, Goto S, Kanehisa M: An improved scoring scheme for predicting glycan structures from gene expression data. Genome Inform; 2007;18:237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the result we applied the proposed method to predicting cancer-specific glycan structures from gene expression profiles for patients of acute lymphocytic leukemia (ALL) and acute myelocytic leukemia (AML).
  • [MeSH-minor] Humans. Leukemia, Myeloid, Acute / genetics. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546491.001).
  • [ISSN] 0919-9454
  • [Journal-full-title] Genome informatics. International Conference on Genome Informatics
  • [ISO-abbreviation] Genome Inform
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Polysaccharides
  •  go-up   go-down


95. Kyrieleis HA, Wilsterman ME, Severijnen RS, van Die CE, Bongaerts GP, Gidding CE: [Pneumatosis intestinalis in 9 children with an oncologic disease]. Ned Tijdschr Geneeskd; 2005 Mar 19;149(12):647-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pneumatosis intestinalis in 9 children with an oncologic disease].
  • OBJECTIVE: To acquire knowledge regarding the rare condition pneumatosis intestinalis (PI) in children treated for malignant disease.
  • METHOD: In 1998-1999 PI was diagnosed in 9 of the 140 children with malignant disease in the department of Paediatric Oncology of the UMC St Radboud, Nijmegen, the Netherlands.
  • In 7 patients the underlying disease was acute lymphocytic leukaemia and in 2 it was a stage IV neuroblastoma.
  • CONCLUSION: With supportive care, PI in children with malignant disease is mostly a self-limiting condition.
  • [MeSH-major] Neuroblastoma / complications. Pneumatosis Cystoides Intestinalis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Prognosis. Retrospective Studies


96. Chen CH, Lin YW, Zhang X, Chou TC, Tsai TJ, Kapuriya N, Kakadiya R, Su TL: Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings. Eur J Med Chem; 2009 Jul;44(7):3056-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of 9-anilinoacridines having an alkylating N-mustard pharmacophore on both anilino (C-3' or C-4') and acridine (C-4) rings with O-ethyl (O-C(2)) or O-butyl (O-C(4)) spacer were synthesized to evaluate their cytotoxicity against human lymphoblastic leukemia (CCRF-CEM) cell growth in vitro.
  • [MeSH-major] Amsacrine / analogs & derivatives. Aniline Compounds / chemistry. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Mustard Compounds / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Humans

  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. Aniline .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752869.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Mustard Compounds; 00DPD30SOY / Amsacrine; 3340-22-5 / 9-anilinoacridine; SIR7XX2F1K / aniline
  •  go-up   go-down


97. Molina B, Lassaletta A, Andion M, Gonzalez-Vicent M, López-Pino MA, Madero L: A persistent epidural mass in a child with B-lineage ALL. Pediatr Blood Cancer; 2010 Oct;55(4):727-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidural spinal cord compression as the initial presentation of acute lymphoblastic leukemia (ALL) is a rare and serious complication.
  • Extramedullary disease is rarely reported in patients with ALL.
  • An open biopsy of the residual epidural mass was performed 7 months after diagnosis.
  • We conclude that a persistent epidural mass in patients with ALL may not indicate resistant disease and may require over a year for resolution, even when response to therapy is adequate.
  • [MeSH-major] Epidural Neoplasms / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20535830.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Thoene S, Rawat VP, Heilmeier B, Hoster E, Metzeler KH, Herold T, Hiddemann W, Gökbuget N, Hoelzer D, Bohlander SK, Feuring-Buske M, Buske C: The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia; 2009 Apr;23(4):649-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia.
  • Molecular characterization of acute lymphoblastic leukemia (ALL) has greatly improved the ability to categorize and prognostify patients with this disease.
  • High expression of CDX2 correlated significantly with the ALL subtype pro-B ALL, cALL, Ph(+) ALL and early T-ALL.
  • Functional analyses showed that overexpression of Cdx2 in murine bone marrow progenitors perturbed genes involved in lymphoid development and that depletion of CDX2 in the human ALL cell line Nalm6 inhibited colony formation.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Homeobox. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Bone Marrow Cells / pathology. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Prognosis. Proto-Oncogenes. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158837.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


99. Mishra P, Kumar R, Mahapatra M, Sharma S, Dixit A, Chaterjee T, Choudhry DR, Saxena R, Choudhry VP: Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology; 2006 Oct;11(5):335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis in acute leukemia: a clinico-hematological profile.
  • We studied 130 consecutive cases of acute leukemia over a 2-year period and identified 9 cases (6.9%) with active tuberculosis (TB).
  • Eight patients with TB had acute myeloid leukemia (AML).
  • Patients with AML were more likely to develop TB as compared to patients with acute lymphoblastic leukemia (ALL) despite the wider use of steroids and radiotherapy in ALL protocols {OR 4.41 (CI 0.53-36.44)}.
  • However it is not a commonly described infection in acute leukemia and a high index of suspicion is warranted especially in areas endemic for TB.
  • [MeSH-major] Leukemia / complications. Tuberculosis / etiology
  • [MeSH-minor] Acute Disease. Adult. Antitubercular Agents / therapeutic use. Female. Humans. Incidence. Leukemia, Myeloid. Male. Neutropenia. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607583.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


100. Alonso CN, Meyer C, Gallego MS, Rossi JG, Mansini AP, Rubio PL, Medina A, Marschalek R, Felice MS: BTBD18: A novel MLL partner gene in an infant with acute lymphoblastic leukemia and inv(11)(q13;q23). Leuk Res; 2010 Nov;34(11):e294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BTBD18: A novel MLL partner gene in an infant with acute lymphoblastic leukemia and inv(11)(q13;q23).
  • [MeSH-major] Chromosome Inversion. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598370.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down






Advertisement